Who makes GSK1605786 GSK: formulation B?

GSK1605786 GSK: formulation B is developed by GlaxoSmithKline.

What development phase is GSK1605786 GSK: formulation B in?

GSK1605786 GSK: formulation B is in Phase 1.

Last reviewed 2026-05-14 · How we verify

GSK1605786 GSK: formulation B

GlaxoSmithKline · Phase 1 active Small molecule

At a glance

Generic name	GSK1605786 GSK: formulation B
Sponsor	GlaxoSmithKline
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Assess the Relative Bioavailability of Four New Formulations of GSK1605786 in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GSK1605786 GSK: formulation B CI brief — competitive landscape report
GSK1605786 GSK: formulation B updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI